In the same year, Kataoka et al. made the report of a serum tumor marker predicting the effectiveness of nivolumab in NSCLC patients, revealing that carcinoembryonic antigen (CEA) levels≥13.8 ng/ml were associated with decreased PFS [9]. Here, CEACAM5 is linked to neoplasm.